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PaQ® (CeQur SA) is a simple to use patch-on device which provides set ba-
sal rates and bolus insulin on demand. PaQ® was designed to minimize bar-
riers to insulin therapy.  In addition to feasibility of use, safety and efficacy 
(reported elsewhere), this study analyzed the impact of the use of PaQ® 
on patient reported outcomes (PRO) including; barriers against insulin 
treatment, diabetes related distress and negative attitudes towards insulin 
therapy in twenty patients with type 2 diabetes (T2D) on a stable multiple 
daily injections (MDI)  insulin regimen. This single center, open label, single 
arm study was comprised of three 2-week periods; baseline (MDI), transi-
tion from MDI to PaQ®, and PaQ® treatment.  Three validated question-
naires were completed at the end of the baseline and PaQ® treatment pe-
riods; Barriers to Insulin Treatment – Questionnaire (BIT), Problem Areas In 
Diabetes - Scale (PAID) and Insulin Treatment Appraisal Scale (ITAS). Nine-
teen patients (age 59±5 y, T2D duration 15±7 y, 21% female, A1C 7.7±0.7%) 
completed the questionnaires at the two measurement points. There was 
a strong and significant effect of PaQ® in the mean BIT total score (2.5 to 
2.1, difference (D)=0.4±0.6; p=.01, effect size (d)= 0.70).  Patients percei-
ved less hardship from insulin therapy (overall improvement d=0.35), less 
stigmatization by insulin injection (overall improvement d=0.28) and less 
fear of hypoglycemia (overall reduction d=0.29). Diabetes related distress 
was slightly reduced (PAID 21.7 to 21.0, D=0.7 ±6.7, p = 0.79, d= 10). A non-
significant reduction was also seen in the mean ITAS score (42.80 to 40.80, 
D=2.0 ±6.5, p=.20, d=31). The study is limited by both the uncontrolled 
design and small sample size. However, the results and the moderate to 
large effects sizes suggest that the use of PaQ® has beneficial and clinically 
relevant effects to overcome barriers to and negative appraisal of insulin 
treatment, without increasing other diabetes related distress.
Table 1:   Sample Characteristics
Figure 1:  BIT total score before and 
after PaQ® 
PaQ® (CeQur SA) is a simple to use patch-on device which provides set basal 
rates and bolus insulin on demand. PaQ® replaces daily basal and prandial 
insulin injections. In this study patients went from taking 4 to 8 injections per 
day to receiving 1 injection (cannula placement) every 3 days. This makes 
the handling of insulin treatment in daily routine much easier and there-
fore PaQ® has the potential to reduce barriers to and negative appraisal of 
insulin therapy. In addition to its feasibility of use, safety and efficacy, this 
study analyzed the impact of the use of PaQ® on patient reported outcomes 
(PRO): 1) barriers against insulin treatment, 2) negative attitudes towards in-
sulin therapy and 3) diabetes related distress in patients with type 2 diabetes 
(T2D) on a stable multiple daily injections (MDI) insulin regimen.
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This single center, open label, single arm study was comprised of three 
2-week periods: baseline (MDI), transition from MDI to PaQ®, and PaQ® 
treatment. Three validated questionnaires were completed at the end of the 
baseline and PaQ® treatment periods:
• The Barriers to Insulin Treatment – Questionnaire (BIT) assesses psycho-
logical barriers against insulin treatment. It allows the calculation of a to-
tal score (a higher score signifies more barriers) as well as the calculation 
of 5 sub-scales measuring different psychological aspects of performing 
an insulin therapy: “Fear of injections and self-testing”, “Expectations 
regarding positive insulin-related outcomes”, “Expected hardship from 
insulin therapy”, “Stigmatization by insulin injections” and “Fear of hy-
poglycemia”. All scales are ranging from 0 -10 (minimum to maximum 
barrier or benefit, respectively).
• The Insulin Treatment Appraisal Scale (ITAS) consists of 16 negative and 4 
positive statements which also form the dimensions of the scale (positive 
and negative appraisal). For calculating the total score, the coding of the 
positive items was inversed to acquire a homogenous interpretation. The 
total scale ranges from 0 – 100, the higher the score the more negative 
the appraisal).
• The Problem Areas In Diabetes –Scale (PAID) measures diabetes related 
distress and has a scale range from 0 - 100, with a higher score indica-
ting higher distress.
Non parametric significance tests were used for pre-post comparisons (Wil-
coxon -Test). Effect sizes are represented as Cohen’s d (number of standard 
deviations). 
Nineteen type 2 diabetic patients completed the questionnaires at the two 
measurement points (see table 1). 
• There was a strong and significant effect of PaQ® on the mean BIT total 
score (see figure 1), thus overall barriers to insulin therapy were reduced 
significantly after 2 weeks’ use of PaQ®. The changes in the 5 sub-scales 
before and after the PaQ® use are shown in figure 2. The effect sizes on 
the total BIT-scale and the five sub-scales are depicted in figure 3. The 
total score showed a large effect size (Cohen’s d > 0.5) 4 of 5 sub-scales 
PaQ® was designed to reduce the known barriers to insulin therapy. The data 
from this study suggests barriers to insulin treatment can be significantly 
reduced with the use of PaQ®. The effect sizes of the sub-scales indicate that 
reduction of “hardship of insulin therapy”, “less feelings of stigmatization” 
and “less fear about hypoglycemia” seemed to be most important in overall 
reduction of Barriers to Insulin Treatment. Reduction of “hardship of insulin 
treatment” and “feeling of stigmatization” might be explained by the fact 
that the use of PaQ® replaced on average 5.2 daily insulin injections. It is 
unclear what led to “less fear of hypoglycemia”, although a hypothesis came 
from post study interviews where several study participants credited the 
constant insulin delivery for improved control. Negative appraisal of insulin 
treatment was reduced after the use of PaQ®, but more positive views on 
insulin treatment were not observed. Diabetes related distress was slightly 
reduced, suggesting that PaQ® use was not associated with an increased 
burden of living with diabetes. The study is limited by both, the uncontrolled 
design and small sample size. However, the results and the moderate to lar-
ge effects sizes suggest that the use of PaQ® has beneficial and clinically 
relevant effects to overcome barriers to and negative appraisal of insulin 
treatment, without increasing other diabetes related distress.
Future studies will elucidate whether PaQ®’s ability to reduce barriers to 
insulin treatment will result in improved glycemic control.  
had medium effects (between d>0.2 and d<0.2). After the use of the 
PaQ®, patients experienced less hardship from insulin therapy, reported 
less fear of hypoglycemia, and felt less stigmatized due to insulin therapy. 
• Negative appraisal of insulin treatment, assessed by the ITAS, was also 
reduced (figure 4), but reduction was not significant. 
• Diabetes related distress as measured by the PAID, was reduced after the 
PaQ® use (figure 5). Although reduction of diabetes related distress was 
not significant, PAID results suggest that there is a trend towards a reduc-
tion in diabetes related distress.
• As the effect sizes show (figure 6) the improvement of the total 
ITAS score was rather due to a reduction of negative attitudes towards in-
sulin therapy than to an increase of positive attitudes towards insulin treat-
ment. Compared to the BIT-scale the effect sizes on the others scales are 
much smaller. Improvement of the PAID-score showed only a small effect 
size. 
Figure 2:  Change of BIT sub- scales            
before and after PaQ®
Figure 3:  Effect sizes of the total score and the sub-scales of BIT
Figure 6:  Effect sizes of the total score and the sub-scales of ITAS and the PAID 
score
Figure 4:  ITAS results before and after 
PaQ® 
Figure 5:  PAID results before and after 
PaQ® 
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